Risk said associated with Eli Lilly drug

A new experimental drug from Indianapolis-based Eli Lilly and Co. has been found to have a risk of major bleeding, sometimes even death, a report says.

While the company's new blood thinner called prasugrel has been found to reduce the risk of heart attacks, it also has been found to have an inherent risk of major bleeding, The Indianapolis Star reported Sunday.

A three-year study into the new medication found that patients already at a high risk of bleeding could be harmed by taking the experimental drug.

In some of these patients, that typically include individuals with a history of strokes and the elderly, this increased bleeding can prove to be fatal, the report said.

A spokeswoman for the company said researchers would attempt to adjust the drug's dosage levels to prevent such side effects, but still praised the medication's positive attributes.

"This is very promising news to those with acute coronary syndrome," spokeswoman Janice Chavers told the Star of the prasugrel results.

Copyright 2007 by United Press International

Citation: Risk said associated with Eli Lilly drug (2007, November 5) retrieved 19 March 2024 from https://medicalxpress.com/news/2007-11-eli-lilly-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Low-gluten beer still a risk for those with celiac disease, says study

 shares

Feedback to editors